Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers

Journal of Pharmaceutical Sciences

Volumn 100, Issue 9, 2011, Pages 3854-3861

  Morimoto, Kaori ^a   Kishimura, Kozue ^a   Nagami, Takaaki ^a   Kodama, Nao ^a   Ogama, Yoichiro ^b   Yokoyama, Midori ^b   Toda, Shinya ^b   Chiyoda, Takeshi ^b   Shimada, Rieko ^c   Inano, Akihiro ^c   Kano, Takashi ^a   Tamai, Ikumi ^d   Ogihara, Takuo ^a  

^a TAKASAKI UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b Medical Co LTA Sumida Hospital   (Japan)

^c Neues Corporation   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

Author keywords

Bioavailability; Food interactions; Intestinal absorption; Peptide transporters; Pharmacokinetics

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; PEPTIDE TRANSPORTER 1; WATER;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG HALF LIFE; DRUG URINE LEVEL; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MILK; NONHUMAN; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 79960139944     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22627     Document Type: Article

References (27)

1. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. 2002. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71:11-20.
2. Dresser GK, Spence JD, Bailey DG. 2000. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41-57.
3. de Castro WV, Mertens-Talcott S, Derendorf H, Butterweck V. 2007. Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci 96:2808-17.
4. Terada T, Inui K. 2004. Peptide transporters: Structure, function, regulation, and application for drug delivery. Curr Drug Metab 5:85-94.
5. Nixon SE, Mawer GE. 1970. The digestion and absorption of protein in man. 2. The form in which digested protein is absorbed. Br J Nutr 24:241-258.
6. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, Yan B. 2006. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Exp Pharmacol Ther 319:1477-1484.
7. Massarella JW, He GZ, Dorr A, Nieforth K, Ward P, Brown A. 2000. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol 40:836-843.
8. Ogihara T, Kano T, Wagatsuma T, Wada S, Yabuuchi H, Enomoto S, Morimoto K, Shirasaka Y, Kobayashi S, Tamai I. 2009. Oseltamivir (Tamiflu) is a substrate of peptide transporter 1. Drug Metab Dispos 37:1676-1681.
9. Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H. 2009. Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009: An internet-based cross-sectional survey. Eurosurveill 14:1-4.
10. Morimoto K, Nakakariya M, Shirasaka Y, Kakinuma C, Fujita T, Tamai I, Ogihara T. 2008. Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein. Drug Metab Dispos 36:6-9.
11. Ose A, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Fujita T, Yamamoto A, Sugiyama Y. 2008. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metab Dispos 36:427-34.
12. Yang D, Pearce RE, Wang H, Gaedigk R, Wan YY, Yan B. 2009. Human carboxylesterase HCE1 and HCE2: Ontogenic expression, interindividual variability, and differential hydrolysis of oseltamivir, aspirin, deltamethrin, and permethrin. Biochem Pharmacol 77:238-247.
13. Basic product information of Tamiflu capsule. 19th revision. Tokyo, Japan: Chugai Pharmaceutical Company, Ltd.
14. Herrera-Ruiz D, Wang Q, Cook TJ, Knipp GT. 2001. Spatial expression patterns of peptide transporters in the human and rat gastrointestinal tracts, Caco-2 in vitro cell culture model, and multiple human tissues. AAPS PharmSci 3(1):E9.
15. 19F nuclear magnetic resonance. Magn Reson Med 48:255-261.
16. Oberle RL, Chen TS, Lloyd C, Barnett JL, Owyang C, Meyer J, Amidon GL. 1990. The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterology 99:1275-1282.
17. McCracken GH Jr, Ginsburg CM, Clarsen JC, Thomas ML. 1978. Pharmacologic evaluation of orally administered antibiotics in infants and children: Effect of feeding on bioavailability. Pediatrics 62:738-743.
18. Anderle P, Nielsen CU, Pinsonneault J, Krog PL, Brodin B, Sadée 2006. Genetic variants of human dipeptide transporter PEPT1. J Pharmacol Exp Ther 316:636-646.
19. Bhardwaj RK, Herrera-Ruiz D, Sinko PJ, Gudmundsson OS, Knipp G. 2005. Delineation of human peptide transporter 1 (hPepT1)-mediated uptake and transport of substrates with varying transporter affinities utilizing stably transfected hPepT1/Madin-Darby canine kidney clones and Caco-2 cells. J Pharmacol Exp Ther 314:1093-100.
20. Schentag JJ, Hill G, Chu T, Rayner CR. 2007. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J Clin Pharmacol 47:689-96.
21. Snell P, Dave N, Wilson K, Rowell L, Weil A, Galitz L, Robson R. 2005. Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate. Br J Clin Pharmacol 59:598-601.
22. Oberle RL, Amidon GL. 1987. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J Pharmacokinet Biopharm 15:529-544.
23. Pedersen PV, Miller R. 1980. Pharmacokinetics of dixycycline reabsorption. J Pharm Sci 69:204-207.
24. Wagner JG. 1984. Unusual pharmacokinetics. In Pharmacokinetics, a modern view; Benet LZ. Levy G, Ferraiolo BL, Eds.. New York: Plenum Press, pp 173-189.
25. Ogihara T, Kamiya M, Ozawa M, Fujita T, Yamamoto A, Yamashita S Ohnishi S, Isomura Y. 2006. What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine. Drug Metab Pharmacokinet 21:238-244.
26. Gilbert ER, Wong EA, Webb KE. 2008. Peptide absorption and utilization: Implication for animal nutrition and health. J Anim Sci 86:2135-2155.
27. Bencharit S, Edwards CC, Morton CL, Howard-Williams EL, Kuhn P, Potter PM, Redinbo MR. 2006. Multisite promiscuity in the processing of endogenous substrates by human carboxylesterase 1. J Mol Biol 63:201-214.